By Fineline Cube 
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), a China-based company, reported its 2025 semi-annual results, showing a year-on-year (YOY) revenue increase of 74.4% to RMB 355 million. The net loss narrowed by 12% to RMB 378 million, while R&D expenses rose by 6.66% to RMB 408 million. As of the reporting date, the company held RMB 2.251 billion in cash and cash equivalents.
Core Product Performance
In the first half of 2025, Dizal’s core products, EGFR tyrosine kinase inhibitor (TKI) sunvozertinib and JAK1-selective inhibitor golidocitinib, achieved strong sales growth following their inclusion in the National Reimbursement Drug List (NRDL).
International Milestones
July 2025 marked significant progress in Dizal’s internationalization efforts. Sunvozertinib received FDA approval in the United States via priority review. It is the first domestically developed innovative drug approved by the FDA for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, heralding further growth potential.-Fineline Info & Tech